Europe,
April 2022
PharmaBoardroom’s latest report, InFigures: European Pharma Hotspots 2022 features up-to-date datasets from six major European pharma hubs.
Europe is the world’s second biggest pharma market region and boasts the headquarters of some of the world’s largest pharma companies. Despite this, in recent years the region has lagged behind both North America as well as East Asia in terms of big industry investments and breakthrough innovations. However, growth prospects are encouraging. IQVIA projects that Europe’s USD 289 billion pharma market is set to grow at a CAGR of 3.9 percent up to 2025, a faster rate than Japan (-0.6 percent), Oceania (2.6 percent), and North America (3.1 percent), and roughly in line with the global average of 4.0 percent.
Covering everything from macroeconomy to healthcare systems, domestic pharma markets, leading companies, exports and imports, biotech investments and clinical trials, this exclusive new report is an excellent jumping-off point for those looking to learn more about the region.
This new report focuses on six European pharma hotspots: France, Germany, Italy, Spain, Switzerland, and the UK. All these countries are home to globally relevant scientific institutions, international pharma companies, innovative biotech start-ups, key opinion leaders, and manufacturing footprints. While Switzerland lacks the domestic market size of these other countries, it punches well above its weight on a host of other metrics.
PharmaBoardroom’s latest report, InFigures: European Pharma Hotspots 2022 features up-to-date datasets from six major European pharma hubs.
Europe is the world’s second biggest pharma market region and boasts the headquarters of some of the world’s largest pharma companies. Despite this, in recent years the region has lagged behind both North America as well as East Asia in terms of big industry investments and breakthrough innovations. However, growth prospects are encouraging. IQVIA projects that Europe’s USD 289 billion pharma market is set to grow at a CAGR of 3.9 percent up to 2025, a faster rate than Japan (-0.6 percent), Oceania (2.6 percent), and North America (3.1 percent), and roughly in line with the global average of 4.0 percent.
Covering everything from macroeconomy to healthcare systems, domestic pharma markets, leading companies, exports and imports, biotech investments and clinical trials, this exclusive new report is an excellent jumping-off point for those looking to learn more about the region.
This new report focuses on six European pharma hotspots: France, Germany, Italy, Spain, Switzerland, and the UK. All these countries are home to globally relevant scientific institutions, international pharma companies, innovative biotech start-ups, key opinion leaders, and manufacturing footprints. While Switzerland lacks the domestic market size of these other countries, it punches well above its weight on a host of other metrics.
